Protara Therapeutics (TARA) Research & Development (2013 - 2026)

Protara Therapeutics' Research & Development history runs 14 years deep, the most recent figure standing at $13.6 million for Q1 2026.

• In Q1 2026, Research & Development rose 48.25% year-over-year to $13.6 million; the TTM figure through Mar 2026 stood at $47.0 million (up 42.12% YoY), while the FY2025 annual figure was $42.6 million, up 34.47% from the prior year.
• Research & Development was $13.6 million for Q1 2026 at Protara Therapeutics, up from $13.1 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $13.6 million in Q1 2026 to a low of $3.1 million in Q2 2022.
• Historically, Research & Development has averaged $7.6 million across 5 years, with a median of $7.2 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Research & Development plunged 47.61% in 2022, then surged 134.99% in 2023.
• A 5-year view of Research & Development shows it stood at $5.0 million in 2022, then gained by 27.9% to $6.4 million in 2023, then surged by 48.86% to $9.5 million in 2024, then jumped by 38.16% to $13.1 million in 2025, then climbed by 3.34% to $13.6 million in 2026.
• The last three Research & Development figures came in at $13.6 million (Q1 2026), $13.1 million (Q4 2025), and $9.6 million (Q3 2025), per Business Quant data.